The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Xofluza Enjoys Commanding Lead with 47% Share in October-December, MHLW Data Show
January 28, 2019
-
BUSINESS Takeda’s Specialty Business Unit Boots Up with Entyvio Detailing
January 25, 2019
-
REGULATORY MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo
January 24, 2019
-
BUSINESS Mitsubishi Tanabe Eyes US as 1st Launch Market, Zeroes in on Immunology/CNS: Chief
January 22, 2019
-
BUSINESS Shionogi Facing Xofluza Supply Crunch as Flu Season Gets into Full Swing
January 21, 2019
-
BUSINESS Mitsubishi Tanabe Staffers Tapping New Support System to Balance Work and Infertility, Medical Treatment
January 18, 2019
-
REGULATORY PMDA to Specify Target Overall Review Period for Regenerative Medicine Products: FY2019-2023 Plan
January 17, 2019
-
REGULATORY MHLW Won’t Necessarily Push March Announcement of New Drug Prices: Bureau Head
January 16, 2019
-
BUSINESS Japan Pharma Market Sags 2% in April-December as Pricing Overhaul Weighs: Encise
January 15, 2019
-
REGULATORY PMDA to Raise Fees and Expand Workforce to Boost Review and Safety Measures, GMP Inspection
January 15, 2019
-
COMMENTARY 2019 Likely to Herald Burst of “Regenerative Medicine” Approvals
January 11, 2019
-
REGULATORY MHLW to Revise Biosimilar Guidelines to Increase Efficiency in Development, Review; Final Draft Expected in FY2019
January 10, 2019
-
REGULATORY MHLW Approves Amgen/Astellas’ Evenity, Gilead Sciences’ Epclusa and More
January 9, 2019
-
BUSINESS Takeda Completes £46 Billion Shire Acquisition
January 8, 2019
-
REGULATORY MHLW to Follow Up on Drug Makers’ Efforts to Observe New Detailing Guidelines
January 7, 2019
-
BUSINESS Can Daiichi Sankyo Take Big Leap in Oncology with 3 FDA Nods in FY2019?
January 4, 2019
-
BUSINESS Reata Developing Sakigake Designated DKD Drug for Alport Syndrome in Japan
December 28, 2018
-
BUSINESS Biogen Japan Set to “Make Impossible Possible” in Next 5 Years, Double Neuroscience Pipeline
December 27, 2018
-
TRENDS Top 10 PHARMA JAPAN Stories in 2018
December 26, 2018
-
BUSINESS Some Drug Makers Stop Distributing 2019 Calendars with Revised JPMA Code of Practice Set to Take Effect in January
December 25, 2018
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…